HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors

Clinical trial NCT06515314 · RECRUITING

Trial details

NCT number: NCT06515314
Sponsor: Shanghai Ruiliyuan Biotechnology Co., Ltd.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Hepatic Cell Carcinoma

Start date: 2024-10-17
Primary completion: 2026-08-10
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.